Abstract
Background and Objectives: Early detection of chronic diseases is essential for improving health outcomes and reducing long-term complications. In Poland, the POZ PLUS pilot programme introduced the Health Check-up (Bilans Zdrowia, BZ) tool, a structured preventive assessment designed to support early identification of chronic conditions in primary care. This study aimed to assess the association between participation in the Health Check-up and the detection (diagnostic yield) of hypertension, type 2 diabetes, lipid metabolism disorders, elevated fasting blood glucose, hypothyroidism, and non-toxic goiter by comparing outcomes in an intervention group and a control group. Materials and Methods: A non-randomised comparative study was conducted using routine clinical data from Health Check-ups performed within the POZ PLUS pilot. Detection rates were compared with those obtained in standard primary care practice during the same period. The study group consisted of 865 adults who met the inclusion criteria and underwent the BZ procedure, while the control group comprised 3199 patients with comparable eligibility who received usual care. Data analysis was performed using R and RStudio. Results: Hypertension detection was similar in both groups: 4.6% (95% CI: 3.3-6.3%) in the intervention group versus 4.5% (95% CI: 3.8-5.3%) in the control group (p = 0.9505). No significant difference was observed in type 2 diabetes detection: 0.7% (95% CI: 0.3-1.5%) versus 0.4% (95% CI: 0.2-0.7%) (p = 0.4134). In contrast, detection rates were significantly higher in the Health Check-up group for lipid metabolism disorders (10.3% vs. 2.6%; p < 0.001), abnormal fasting glucose (2.9% vs. 1.8%; p = 0.0465), and thyroid diseases, including hypothyroidism and non-toxic goiter (4.3% vs. 2.3%; p = 0.0016). Conclusions: The Health Check-up tool was associated with higher detection rates of lipid disorders, impaired fasting glucose, and thyroid diseases compared with usual care, suggesting increased diagnostic yield under a structured preventive assessment pathway. Further research should evaluate downstream clinical outcomes and cost-effectiveness. Given the non-randomised design and differential diagnostic intensity between groups, these findings should be interpreted as associations with diagnostic yield rather than causal effects on disease incidence or clinical outcomes.